J Sainz1, E Pérez, S Gómez-Lopera, M Jurado. 1. Unidad de Investigación, Hospital Universitario Virgen de las Nieves, Granada, Spain. jsainz@ugr.es
Abstract
OBJECTIVE: The aim of this study was to determine whether interleukin-1 alpha (IL1alpha), interleukin-1 beta (IL1beta), and IL1 receptor antagonist (IL1Ra) polymorphisms are implicated in invasive pulmonary aspergillosis (IPA) pathogenesis. MATERIALS AND METHODS: Subjects comprised 110 hematological patients and 148 healthy controls. Genotypic and allelic frequencies were similar between hematological patients and controls. IPA was diagnosed in 59 of the 110 patients according to consensus criteria published by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/IFICG). RESULTS AND DISCUSSIONS: Individual locus analysis showed that IL1alpha and IL1Ra polymorphisms were not associated with the presence of IPA (p = 0.560 and p = 0.680, respectively). However, a trend towards a higher presence of IL1beta( - ) (511TT) genotype (or IL1beta(-511T) allele) in the IPA group than in the non-IPA patient group (p = 0.092 and p = 0.095, respectively) was found. Haplotype analysis revealed that VNTR2/-889C/-511T haplotype was strongly associated with susceptibility to develop IPA infection (p = 0.020). Haplotype analysis also showed an association between VNTR2/-889C/-511C haplotype and resistance to IPA infection (p = 0.028). Furthermore, patients with IL1Ra VNTR2/2 and IL1beta(-511)T/T genotypes had a higher positive serum galactomannan percentage versus patients with other genotypes. Finally, C-reactive protein (CRP) production was significantly associated with IL1 gene cluster polymorphisms, although CRP values were similar between IPA and non-IPA groups. CONCLUSION: These findings indicate a critical role of IL1 gene cluster polymorphisms in the susceptibility to IPA infection and CRP production.
OBJECTIVE: The aim of this study was to determine whether interleukin-1 alpha (IL1alpha), interleukin-1 beta (IL1beta), and IL1 receptor antagonist (IL1Ra) polymorphisms are implicated in invasive pulmonary aspergillosis (IPA) pathogenesis. MATERIALS AND METHODS: Subjects comprised 110 hematological patients and 148 healthy controls. Genotypic and allelic frequencies were similar between hematological patients and controls. IPA was diagnosed in 59 of the 110 patients according to consensus criteria published by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/IFICG). RESULTS AND DISCUSSIONS: Individual locus analysis showed that IL1alpha and IL1Ra polymorphisms were not associated with the presence of IPA (p = 0.560 and p = 0.680, respectively). However, a trend towards a higher presence of IL1beta( - ) (511TT) genotype (or IL1beta(-511T) allele) in the IPA group than in the non-IPA patient group (p = 0.092 and p = 0.095, respectively) was found. Haplotype analysis revealed that VNTR2/-889C/-511T haplotype was strongly associated with susceptibility to develop IPA infection (p = 0.020). Haplotype analysis also showed an association between VNTR2/-889C/-511C haplotype and resistance to IPA infection (p = 0.028). Furthermore, patients with IL1Ra VNTR2/2 and IL1beta(-511)T/T genotypes had a higher positive serum galactomannan percentage versus patients with other genotypes. Finally, C-reactive protein (CRP) production was significantly associated with IL1 gene cluster polymorphisms, although CRP values were similar between IPA and non-IPA groups. CONCLUSION: These findings indicate a critical role of IL1 gene cluster polymorphisms in the susceptibility to IPA infection and CRP production.
Authors: J E Wang; A Warris; E A Ellingsen; P F Jørgensen; T H Flo; T Espevik; R Solberg; P E Verweij; A O Aasen Journal: Infect Immun Date: 2001-04 Impact factor: 3.441
Authors: J E Sims; C J March; D Cosman; M B Widmer; H R MacDonald; C J McMahan; C E Grubin; J M Wignall; J L Jackson; S M Call Journal: Science Date: 1988-07-29 Impact factor: 47.728
Authors: F Arnalich; D López-Maderuelo; R Codoceo; J Lopez; L M Solis-Garrido; C Capiscol; C Fernandez-Capitán; R Madero; C Montiel Journal: Clin Exp Immunol Date: 2002-02 Impact factor: 4.330
Authors: Salamatu S Mambula; Keya Sau; Philipp Henneke; Douglas T Golenbock; Stuart M Levitz Journal: J Biol Chem Date: 2002-08-08 Impact factor: 5.157
Authors: C G Parks; G S Cooper; M A Dooley; E L Treadwell; E W St Clair; G S Gilkeson; J P Pandey Journal: Ann Rheum Dis Date: 2004-01 Impact factor: 19.103
Authors: Juliane Macheleidt; Kirstin Scherlach; Toni Neuwirth; Wolfgang Schmidt-Heck; Maria Straßburger; Joseph Spraker; Joshua A Baccile; Frank C Schroeder; Nancy P Keller; Christian Hertweck; Thorsten Heinekamp; Axel A Brakhage Journal: Mol Microbiol Date: 2015-03-11 Impact factor: 3.501
Authors: Alayna K Caffrey-Carr; Caitlin H Kowalski; Sarah R Beattie; Nathan A Blaseg; Chanell R Upshaw; Arsa Thammahong; Hannah E Lust; Yi-Wei Tang; Tobias M Hohl; Robert A Cramer; Joshua J Obar Journal: Infect Immun Date: 2017-11-17 Impact factor: 3.441
Authors: Jaleesa M Garth; Kristen M Reeder; Matthew S Godwin; Joseph J Mackel; Chad W Dunaway; Jonathan P Blackburn; Chad Steele Journal: J Immunol Date: 2017-08-07 Impact factor: 5.422
Authors: Denise A Gonzales; Carlos De Torre; Honghui Wang; Christopher B Devor; Peter J Munson; Sai-Xia Ying; Steven J Kern; Ruta Petraitiene; David L Levens; Thomas J Walsh; Anthony F Suffredini Journal: Proteomics Date: 2010-12 Impact factor: 3.984
Authors: Sabina Cauci; Manuela Di Santolo; Kelli K Ryckman; Scott M Williams; Giuseppe Banfi Journal: BMC Med Genet Date: 2010-02-22 Impact factor: 2.103